质子泵抑制剂与肝硬化并发症的研究进展

刘林祥; 聂源; 朱萱

doi:10.3969/j.issn.1001-5256.2020.11.036

质子泵抑制剂与肝硬化并发症的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.11.036

南昌大学第一附属医院消化内科江西省消化疾病研究所

基金项目:

国家科学自然基金（81960120）；江西省赣鄱英才“555”领军人才项目；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 804
- HTML全文浏览量: 58
- PDF下载量: 102
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-16
- 出版日期: 2020-11-20

Research advances in proton pump inhibitor and complications of liver cirrhosis

Department of Gastroenterology,The First Affiliated Hospital of Nanchang University & Jiangxi Institute of Digestive Diseases

Research funding:

摘要

摘要:
质子泵抑制剂（PPI）常用于预防或治疗消化系统疾病,然而使用PPI导致的不良结局日益受到学者关注。阐述了上消化道出血、自发性腹膜炎、肝性脑病、肝细胞癌和感染等肝硬化并发症以及肠道菌群变化与使用PPI之间的关系,提出临床上应掌握好PPI用药原则,了解PPI可能带来的并发症风险,积极改善因用药引起的并发症。
- 肝硬化 /
- 质子泵抑制剂 /
- 胃肠出血 /
- 腹膜炎 /
- 肝性脑病 /
- 癌,肝细胞 /
- 胃肠道微生物组
Abstract:
Proton pump inhibitor( PPI) is often used for the prevention and treatment of digestive system diseases,and the adverse outcomes caused by the use of PPI are increasingly concerned by scholars. This article elaborates on the association of the complications of liver cirrhosis,such as upper gastrointestinal bleeding,spontaneous bacterial peritonitis,hepatic encephalopathy,hepatocellular carcinoma,and infection,and the change in gut microbiota with the use of PPI,and points out that in clinical practice,it is important to master the medication rules of PPI,understand the risk of complications caused by PPI,and actively improve the complications caused by medication.
- liver cirrhosis /
- proton pump inhibitors /
- gastrointestinal hemorrhage /
- peritonitis /
- hepatic encephalopathy /
- carcinoma,hepatocellular /
- gastrointestinal microbiome

HTML全文

参考文献(37)

[1] CHEN CL,MAO H. The potential application of proton pump inhibitors in cirrhosis[J]. Chin Hepatol,2010,15(6):470-472.(in Chinese)陈春林，毛华．质子泵抑制剂在肝硬化治疗中的应用可能性[J]．肝脏，2010,15(6):470-472.

[2] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Endoscopy,Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):203-217.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219.

[3] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.

[4] DAM G,VILSTRUP H,WATSON H,et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites[J]. Hepatology,2016,64(4):1265-1272.

[5] MACLAREN R,REYNOLDS PM,ALLEN RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit[J]. JAMA Intern Med,2014,174(4):564-574.

[6] DULTZ G,PIIPER A,ZEUZEM S,et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis[J]. Aliment Pharmacol Ther,2015,41(5):459-466.

[7] COLE HL,PENNYCOOK S,HAYES PC. The impact of proton pump inhibitor therapy on patients with liver disease[J]. Aliment Pharmacol Ther,2016,44(11-12):1213-1223.

[8] STANLEY AJ,LAINE L. Management of acute upper gastrointestinal bleeding[J]. BMJ,2019,364:l536.

[9] SREEDHARAN A,MARTIN J,LEONTIADIS GI,et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding[J]. Cochrane Database Syst Rev,2010,7:CD005415.

[10] LIN L,CUI B,DENG Y,et al. The efficacy of proton pump inhibitor in cirrhotics with variceal bleeding:A systemic review and Meta-analysis[J]. Digestion,2020.[Online ahead of print]

[11] TAKEUCHI Y,KITANO S,BANDOH T,et al. Acceleration of gastric ulcer healing by omeprazole in portal hypertensive rats. Is its action mediated by gastrin release and the stimulation of epithelial proliferation?[J]. Eur Surg Res,2003,35(2):75-80.

[12] ARDEVOL A,IBANEZ-SANZ G,PROFITOS J,et al. Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies[J]. Hepatology,2018,67(4):1458-1471.

[13] BAJAJ JS,ZADVORNOVA Y,HEUMAN DM,et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites[J]. Am J Gastroenterol,2009,104(5):1130-1134.

[14] YAMAMOTO K,ISHIGAMI M,HONDA T,et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients[J]. Hepatol Int,2019,13(2):234-244.

[15] DAM G,VILSTRUP H,ANDERSEN PK,et al. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites[J]. Liver Int,2019,39(3):514-521.

[16] LIN L,HOU L,DENG Y,et al. Acid suppression therapy and its association with spontaneous bacterial peritonitis incidence:A systemic review and meta-analysis[J]. Hepatol Res,2020,50(2):233-245.

[17] TERG R,CASCIATO P,GARBE C,et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis:A multicenter prospective study[J]. J Hepatol,2015,62(5):1056-1060.

[18] CAMPBELL MS,OBSTEIN K,REDDY KR,et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis[J]. Dig Dis Sci,2008,53(2):394-398.

[19] ZHU J,QI X,YU H,et al. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis[J]. United European Gastroenterol J,2018,6(8):1179-1187.

[20] KUAN YC,HUANG KW,LIN CL,et al. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis[J]. J Clin Med,2019,8(8):1108.

[21] LEWIS DS,LEE TH,KONANUR M,et al. Proton pump inhibitor use is associated with an increased frequency of new or worsening hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. J Vasc Interv Radiol,2019,30(2):163-169.

[22] SHI D,ZHOU Z,DAI Y,et al. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients:A systematic review with meta-analysis[J]. Clin Drug Investig,2019,39(9):847-856.

[23] TARANTINO G,CONCA P,BASILE V,et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease[J]. Hepatol Res,2007,37(6):410-415.

[24] SHAO YJ,CHAN TS,TSAI K,et al. Association between proton pump inhibitors and the risk of hepatocellular carcinoma[J]. Aliment Pharmacol Ther,2018,48(4):460-468.

[25] NAKATAKE R,HISHIKAWA H,KOTSUKA M,et al. The proton pump inhibitor lansoprazole has hepatoprotective effects in in vitro and in vivo rat models of acute liver injury[J]. Dig Dis Sci,2019,64(10):2854-2866.

[26] KAO WY,SU CW,CHIA-HUI TAN E,et al. Proton pump inhibitors and risk of hepatocellular carcinoma in patients with chronic hepatitis B or C[J]. Hepatology,2019,69(3):1151-1164.

[27] SONG HJ,JIANG X,HENRY L,et al. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease:A systematic review and meta-analysis[J]. Eur J Clin Pharmacol,2020,76(6):851-866.

[28] WANG J,WU Y,BI Q,et al. Adverse outcomes of proton pump inhibitors in chronic liver disease:A systematic review and meta-analysis[J]. Hepatol Int,2020,14(3):385-398.

[29] STADLBAUER V,KOMAROVA I,KLYMIUK I,et al. Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis[J]. Liver Int,2020,40(4):866-877.

[30] WOODHOUSE CA,PATEL VC,SINGANAYAGAM A,et al.Review article:The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J].Aliment Pharmacol Ther,2018,47(2):192-202.

[31] ZHERNAKOVA A,KURILSHIKOV A,BONDER MJ,et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science,2016,352(6285):565-569.

[32] LI Z,ZHANG W,JIA L,et al. Advances in the clinical application of high-throughput sequencing in detecting microbiota in cirrhotic ascites,serum,and feces[J]. J Clin Hepatol,2020,36(4):900-903.(in Chinese)李真，张维，贾琳，等．高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用[J]．临床肝胆病杂志，2020,36(4):900-903.

[33] HATTON G,SHAWCROSS DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?[J]. Expert Rev Gastroenterol Hepatol,2019,13(1):1-2.

[34] OKURA Y,NAMISAKI T,SATO S,et al. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis[J]. Hepatol Res,2019,49(2):232-238.

[35] SU T,LAI S,LEE A,et al. Meta-analysis:Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth[J]. J Gastroenterol,2018,53(1):27-36.

[36] FRANCO DL,DISBROW MB,KAHN A,et al. Duodenal aspirates for small intestine bacterial overgrowth:Yield,PPIs,and outcomes after treatment at a tertiary academic medical center[J]. Gastroenterol Res Pract,2015,2015:971582.

[37] JANKA T,TORNAI T,BORBELY B,et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis[J].Eur J Gastroenterol Hepatol,2020,32(2):257-264.

施引文献

资源附件(0)

访问统计